𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib

✍ Scribed by Naveen S. Basappa; Paul Elson; Ali-Reza Golshayan; Laura Wood; Jorge A. Garcia; Robert Dreicer; Brian I. Rini

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
224 KB
Volume
117
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Prognostic nomogram for sunitinib in pat
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
✍ Robert J. Motzer; Ronald M. Bukowski; Robert A. Figlin; Thomas E. Hutson; M. Dro πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy over interferon‐alfa as first‐line therapy in patients with metastatic clear‐cell renal cell carcinoma (RCC). On the basis of outcome data from that trial, the authors developed a nomogram for predi

Phase 2 trial of talactoferrin in previo
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
✍ Eric Jonasch; Walter M. Stadler; Ronald M. Bukowski; Teresa G. Hayes; Atul Varad πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Talactoferrin (TLF), a recombinant form of human lactoferrin (hLF), is an immunomodulatory iron‐binding glycoprotein first identified in breast milk. Its immunomodulatory functions include activation of natural killer (NK) and lymphokine‐activated killer cells and enhanc